Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atossa TherapeuticsATOS -0.84%26 Cash-to-Debt is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates ATOS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,398 Biotechnology companies, Atossa Therapeutics ranks better than 99.71% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Atossa Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2026 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Atossa Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Atossa Therapeutics's Cash-to-Debt or its related term are showing as below:
ATOS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 165.84 Med: No Debt Max: 140041
Current: No Debt
During the past 13 years, Atossa Therapeutics's highest Cash to Debt Ratio was 140041.00. The lowest was 165.84. And the median was No Debt.
ATOS's Cash-to-Debt is ranked better than 99.71% of 1398
companies
in the Biotechnology industry
Industry Median: 6.21
vs ATOS: No Debt
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Atossa Therapeutics Cash-to-Debt Related Terms
Atossa Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Atossa Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Atossa Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atossa Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Atossa Therapeutics's Cash-to-Debt falls into.
Atossa Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
Atossa Therapeutics had no debt (1).
Atossa Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2026 is calculated as:
Atossa Therapeutics had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Atossa Therapeutics (ATOS) has a Cash-to-Debt of No Debt (1) as of Mar. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Atossa Therapeutics' Cash-to-Debt has ranged from 165.84 to 140,041.00. According to the industry distribution chart, Atossa Therapeutics ranks #4 out of 1398 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Atossa Therapeutics' Cash-to-Debt too high?
Atossa Therapeutics' current Cash-to-Debt of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 165.84 to a high of 140,041.00. Based on the distribution chart, Atossa Therapeutics ranks #4 out of 1398 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atossa Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' Cash-to-Debt compare to SKYE and JSPR?
According to the Biotechnology industry distribution chart, Atossa Therapeutics ranks #4 out of 1398 companies for Cash-to-Debt. This places Atossa Therapeutics in the top 0% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.21. Historically, Atossa Therapeutics' own Cash-to-Debt has ranged from 165.84 to 140,041.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.21, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atossa Therapeutics's current Cash-to-Debt is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Atossa Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current Cash-to-Debt is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score
Get the complete analysis for ATOS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATOS has been successfully added to your 
